reports
- Livio Luyten
Holdings Report - December 2025 Discussing our recent target price inc...
We're excited to share our latest views on two compelling investment companies within the holdings universe. Brederode's robust Q3 operational momentum and wide ~28% NAV discount prompt a cautious upgrade to Accumulate (€125 TP maintained). Whitestone's €70m capital raise at NAV premium, backed by strong shareholders and GFI's gold tailwinds, is a positive catalyst that led us to raise our TP to €18.0 (from €15.0). Click below to read the full updates.
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Galapagos Initiates wind-down of cell Tx after conclusion of works cou...
Galapagos announced that the previously reported works council consultation process regarding the wind-down of cell therapy activities has now been completed and its Board of Directors has decided to initiate the wind-down of the company's cell therapy activities. This decision follows a strategic review and sale process in 2025 where no viable offers emerged. We believe the wind-down creates clarity and, once completed, will allow management to move forward with their plan of building a new pip...
- Lynn Hautekeete
Aedifica Refuelling the pipeline ahead of imminent BCA decision
Aedifica announced € 108.5m new healthcare investments across Europe in a mixture of new forward funded developments, extensions and acquisitions. Aedifica still awaits the approval of the Belgian competition authorities (BCA) to open its exchange period. In our timeline, a decision is expected by 15/01. As a remedy, Aedifica suggested € 300.0m Belgian asset disposals in the coming years. As argued in earlier notes (See: better too early than sorry), Aedifica needs new investments at 6.5% net yi...
- Wim Lewi
Warehouses De Pauw Asset rotation deal from Liège (BE) to Le Havre (FR...
WDP started 2026 well with the acquisition of a prime logistics site in the Port of Le Havre, France's main container terminal, for €58m. At the same time, WDP disposed of a vacant asset in Liège (Airport), Belgium, generating €35m. Both are on long term concession land. The Le Havre site includes two Grade A logistics buildings (65k sqm) and a 40k sqm container yard, fully let to Seafrigo under a triple net lease until 2033. This investment yields a 6.0% NOI and strengthens WDP's critical mass ...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Lynn Hautekeete
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
argenx Karen Massey to become new CEO
argenx announced that Karen Massey, current COO, will transition to CEO and executive director and Tim Van Hauwermeiren, current CEO, will transition to non-executive director and chairman of the board. We believe Karen is a strong fit for the CEO role as an internal candidate who, in her capacity as COO, helped shape the company's Vision 2030 and built its commercial engine. Based on our conversation with management, Karen will focus on ensuring continuity and executing argenx' strategy, while...
- Wim Hoste
Umicore Walking on Sunshine - increasing target price to € 21
We upgrade our forecasts for the coming years with our 2030E adjusted EBITDA estimate upped by c. 8%. Loosening EU standards on CO2 emission regulation for cars & vans provide some additional support to the Catalysts business, whilst we have kept our forecasts for Battery Materials unchanged as these were already below the company's CMD targets and upside to our numbers will have to come from new supply arrangements/partnerships. The very strong metal price environment will most likely allow Umi...
- Livio Luyten
Ackermans & van Haaren A deep dive into the moat and valuation of the ...
AvH's private banking segment (~50% of NAV), comprising Delen Private Bank (DPB) and Bank Van Breda (BVB), delivered outstanding performance YTD. This was driven by stable ownership, structural synergies, and superior execution in their niches. DPB excels through its focus on discretionary mandates, successful buy-and-build, record inflows, and investments in digital/client experience. This resulted in top-tier client satisfaction and exceptional efficiency that supported strong profitability. B...
- Hilde Van Boxstael
- Wim Lewi
- Wim Lewi
Ascencio Acquires retail park is South-East of France for €22.8m
Ascencio acquired the Horizon Provence retail park in Monteux, southeastern France, for €22.8 million (excl. VAT). Covering over 12,000 m², the park hosts around 20 stores focused on quality food retail, including Super U and Maison des Agriculteurs. This is in line with the food centered strategy of Ascencio. Complementary brands such as Krys, Marie Blachère, and Basic Fit enhance the commercial mix. Located in a tourist and residential area in Provence-Alpes-Côte d'Azur, the site benefits from...
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Hilde Van Boxstael
- Livio Luyten
- Michiel Declercq
- Wim Lewi
- Guy Sips
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Wim Hoste
Titan New strategic partnership in advanced mortars
Titan announced a new strategic partnership in advanced mortars, which fits well within the Forward 2029 Strategic plan which was presented last month, and which targets to grow EBITDA by 62% to € 1bn by 2029 on a combination of organic growth initiatives and M&A in regions where the company has an established footprint and acquisitions offer sizeable synergies potential. Overall, TITAN is seeking growth in the coming years in both its core heavy materials businesses as well as through growing i...
- Guy Sips
- Hilde Van Boxstael
- Wim Lewi
- Jacob Mekhael
Galapagos GLPG3667 phase 2 hits topline in DM, but misses in SLE
Galapagos announced the topline results from 2 phase 2 studies evaluating the efficacy and safety of GLPG3667 (TYK2 inhibitor) in dermatomyositis (DM, GALARISSO study) and active systemic lupus erythematosus (SLE, GALACELA study). The GALARISSO study in DM met its primary endpoint showing a 14.26 delta on the TIS measure at 24 weeks, which compares favourably to brepocitinib (TYK2/JAK1 inhibitor) in our view. In the GALACELA study in SLE patients, primary endpoint at 32 weeks was not met, but fi...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Michiel Declercq
- Thibault Leneeuw
- Wim Lewi
- Kristof Samoy
NX Filtration Trouble comes in fours, yet another profit warning erodi...
NX Filtration just sent out another profit warning. For the fourth time in a row the company confessed it will not be able to realise its issued revenue guidance. At the 1H25 release the company reiterated its FY25 revenue guidance calling for y/y growth in the 50-70% range with KBC est. at the 60% midpoint. Today management warns FY25 revs are expected to be ca. €14m, representing a y/y growth just topping 25%. No quantified insights in profitability and cash position were given but surprisingl...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.